nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—CYP2E1—Methimazole—Graves' disease	0.219	0.347	CbGbCtD
Carvedilol—CYP1A2—Methimazole—Graves' disease	0.127	0.201	CbGbCtD
Carvedilol—CYP2C9—Methimazole—Graves' disease	0.114	0.181	CbGbCtD
Carvedilol—CYP2D6—Methimazole—Graves' disease	0.104	0.166	CbGbCtD
Carvedilol—CYP3A4—Methimazole—Graves' disease	0.0663	0.105	CbGbCtD
Carvedilol—Traumatic liver injury—Propylthiouracil—Graves' disease	0.0133	0.108	CcSEcCtD
Carvedilol—Interstitial pneumonia—Propylthiouracil—Graves' disease	0.0102	0.0836	CcSEcCtD
Carvedilol—Interstitial lung disease—Propylthiouracil—Graves' disease	0.00698	0.057	CcSEcCtD
Carvedilol—Liver injury—Propylthiouracil—Graves' disease	0.00587	0.048	CcSEcCtD
Carvedilol—SELE—connective tissue—Graves' disease	0.00571	0.0432	CbGeAlD
Carvedilol—Aplastic anaemia—Methimazole—Graves' disease	0.00545	0.0446	CcSEcCtD
Carvedilol—VCAM1—eye—Graves' disease	0.00545	0.0413	CbGeAlD
Carvedilol—VCAM1—connective tissue—Graves' disease	0.00525	0.0398	CbGeAlD
Carvedilol—HIF1A—eye—Graves' disease	0.00524	0.0397	CbGeAlD
Carvedilol—GJA1—eye—Graves' disease	0.00509	0.0385	CbGeAlD
Carvedilol—HIF1A—connective tissue—Graves' disease	0.00505	0.0383	CbGeAlD
Carvedilol—GJA1—connective tissue—Graves' disease	0.0049	0.0371	CbGeAlD
Carvedilol—Aplastic anaemia—Propylthiouracil—Graves' disease	0.00464	0.0379	CcSEcCtD
Carvedilol—ADRB3—connective tissue—Graves' disease	0.00449	0.034	CbGeAlD
Carvedilol—NDUFC2—eye—Graves' disease	0.00443	0.0335	CbGeAlD
Carvedilol—SELE—pituitary gland—Graves' disease	0.0044	0.0333	CbGeAlD
Carvedilol—SELE—adipose tissue—Graves' disease	0.00438	0.0332	CbGeAlD
Carvedilol—VCAM1—pituitary gland—Graves' disease	0.00404	0.0306	CbGeAlD
Carvedilol—VCAM1—adipose tissue—Graves' disease	0.00403	0.0305	CbGeAlD
Carvedilol—HIF1A—pituitary gland—Graves' disease	0.00389	0.0295	CbGeAlD
Carvedilol—Renal failure acute—Propylthiouracil—Graves' disease	0.00388	0.0317	CcSEcCtD
Carvedilol—HIF1A—adipose tissue—Graves' disease	0.00388	0.0294	CbGeAlD
Carvedilol—Dermatitis exfoliative—Propylthiouracil—Graves' disease	0.0038	0.0311	CcSEcCtD
Carvedilol—SELE—thyroid gland—Graves' disease	0.00379	0.0287	CbGeAlD
Carvedilol—GJA1—pituitary gland—Graves' disease	0.00377	0.0286	CbGeAlD
Carvedilol—GJA1—adipose tissue—Graves' disease	0.00376	0.0285	CbGeAlD
Carvedilol—VCAM1—thyroid gland—Graves' disease	0.00349	0.0264	CbGeAlD
Carvedilol—ADRB3—adipose tissue—Graves' disease	0.00345	0.0261	CbGeAlD
Carvedilol—HIF1A—thyroid gland—Graves' disease	0.00335	0.0254	CbGeAlD
Carvedilol—NDUFC2—pituitary gland—Graves' disease	0.00329	0.0249	CbGeAlD
Carvedilol—NDUFC2—adipose tissue—Graves' disease	0.00327	0.0248	CbGeAlD
Carvedilol—GJA1—thyroid gland—Graves' disease	0.00325	0.0247	CbGeAlD
Carvedilol—VEGFA—pituitary gland—Graves' disease	0.00298	0.0226	CbGeAlD
Carvedilol—VEGFA—adipose tissue—Graves' disease	0.00297	0.0225	CbGeAlD
Carvedilol—NDUFC2—thyroid gland—Graves' disease	0.00283	0.0215	CbGeAlD
Carvedilol—Alopecia—Methimazole—Graves' disease	0.00258	0.0211	CcSEcCtD
Carvedilol—VEGFA—thyroid gland—Graves' disease	0.00257	0.0195	CbGeAlD
Carvedilol—Haemoglobin—Propylthiouracil—Graves' disease	0.00249	0.0204	CcSEcCtD
Carvedilol—Haemorrhage—Propylthiouracil—Graves' disease	0.00248	0.0203	CcSEcCtD
Carvedilol—Vertigo—Methimazole—Graves' disease	0.00228	0.0187	CcSEcCtD
Carvedilol—Leukopenia—Methimazole—Graves' disease	0.00227	0.0186	CcSEcCtD
Carvedilol—Alopecia—Propylthiouracil—Graves' disease	0.00219	0.0179	CcSEcCtD
Carvedilol—Myalgia—Methimazole—Graves' disease	0.00216	0.0177	CcSEcCtD
Carvedilol—Arthralgia—Methimazole—Graves' disease	0.00216	0.0177	CcSEcCtD
Carvedilol—Oedema—Methimazole—Graves' disease	0.00207	0.0169	CcSEcCtD
Carvedilol—Thrombocytopenia—Methimazole—Graves' disease	0.00203	0.0166	CcSEcCtD
Carvedilol—Vertigo—Propylthiouracil—Graves' disease	0.00194	0.0159	CcSEcCtD
Carvedilol—Leukopenia—Propylthiouracil—Graves' disease	0.00193	0.0158	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Methimazole—Graves' disease	0.00189	0.0154	CcSEcCtD
Carvedilol—Paraesthesia—Methimazole—Graves' disease	0.00186	0.0152	CcSEcCtD
Carvedilol—Somnolence—Methimazole—Graves' disease	0.00184	0.0151	CcSEcCtD
Carvedilol—Myalgia—Propylthiouracil—Graves' disease	0.00184	0.015	CcSEcCtD
Carvedilol—Arthralgia—Propylthiouracil—Graves' disease	0.00184	0.015	CcSEcCtD
Carvedilol—ADRB1—connective tissue—Graves' disease	0.00184	0.0139	CbGeAlD
Carvedilol—Dyspepsia—Methimazole—Graves' disease	0.00182	0.0149	CcSEcCtD
Carvedilol—Oedema—Propylthiouracil—Graves' disease	0.00176	0.0144	CcSEcCtD
Carvedilol—Thrombocytopenia—Propylthiouracil—Graves' disease	0.00172	0.0141	CcSEcCtD
Carvedilol—Urticaria—Methimazole—Graves' disease	0.00165	0.0135	CcSEcCtD
Carvedilol—Body temperature increased—Methimazole—Graves' disease	0.00164	0.0134	CcSEcCtD
Carvedilol—Musculoskeletal discomfort—Propylthiouracil—Graves' disease	0.0016	0.0131	CcSEcCtD
Carvedilol—Paraesthesia—Propylthiouracil—Graves' disease	0.00158	0.0129	CcSEcCtD
Carvedilol—Somnolence—Propylthiouracil—Graves' disease	0.00157	0.0128	CcSEcCtD
Carvedilol—Dyspepsia—Propylthiouracil—Graves' disease	0.00155	0.0127	CcSEcCtD
Carvedilol—Pruritus—Methimazole—Graves' disease	0.00147	0.012	CcSEcCtD
Carvedilol—ADRB1—adipose tissue—Graves' disease	0.00141	0.0107	CbGeAlD
Carvedilol—Urticaria—Propylthiouracil—Graves' disease	0.0014	0.0114	CcSEcCtD
Carvedilol—Body temperature increased—Propylthiouracil—Graves' disease	0.00139	0.0114	CcSEcCtD
Carvedilol—Vomiting—Methimazole—Graves' disease	0.00132	0.0108	CcSEcCtD
Carvedilol—Rash—Methimazole—Graves' disease	0.00131	0.0107	CcSEcCtD
Carvedilol—Dermatitis—Methimazole—Graves' disease	0.00131	0.0107	CcSEcCtD
Carvedilol—Headache—Methimazole—Graves' disease	0.0013	0.0106	CcSEcCtD
Carvedilol—Pruritus—Propylthiouracil—Graves' disease	0.00125	0.0102	CcSEcCtD
Carvedilol—Nausea—Methimazole—Graves' disease	0.00123	0.0101	CcSEcCtD
Carvedilol—Vomiting—Propylthiouracil—Graves' disease	0.00112	0.00916	CcSEcCtD
Carvedilol—ADRA1A—adipose tissue—Graves' disease	0.00111	0.00844	CbGeAlD
Carvedilol—Rash—Propylthiouracil—Graves' disease	0.00111	0.00908	CcSEcCtD
Carvedilol—Dermatitis—Propylthiouracil—Graves' disease	0.00111	0.00908	CcSEcCtD
Carvedilol—ADRA2A—connective tissue—Graves' disease	0.0011	0.00836	CbGeAlD
Carvedilol—Headache—Propylthiouracil—Graves' disease	0.0011	0.00903	CcSEcCtD
Carvedilol—KCNH2—pituitary gland—Graves' disease	0.00108	0.00818	CbGeAlD
Carvedilol—ADRA2C—pituitary gland—Graves' disease	0.00107	0.00807	CbGeAlD
Carvedilol—ADRA2C—adipose tissue—Graves' disease	0.00106	0.00804	CbGeAlD
Carvedilol—Nausea—Propylthiouracil—Graves' disease	0.00105	0.00856	CcSEcCtD
Carvedilol—PTGS1—connective tissue—Graves' disease	0.00104	0.00788	CbGeAlD
Carvedilol—CYP1A1—adipose tissue—Graves' disease	0.000909	0.00688	CbGeAlD
Carvedilol—ADRA2A—pituitary gland—Graves' disease	0.00085	0.00644	CbGeAlD
Carvedilol—ADRA2A—adipose tissue—Graves' disease	0.000847	0.00642	CbGeAlD
Carvedilol—PTGS1—pituitary gland—Graves' disease	0.000801	0.00607	CbGeAlD
Carvedilol—PTGS1—adipose tissue—Graves' disease	0.000798	0.00605	CbGeAlD
Carvedilol—CYP1A2—thyroid gland—Graves' disease	0.000797	0.00604	CbGeAlD
Carvedilol—CYP1A1—thyroid gland—Graves' disease	0.000786	0.00596	CbGeAlD
Carvedilol—ADRA2A—thyroid gland—Graves' disease	0.000733	0.00555	CbGeAlD
Carvedilol—CYP2E1—thyroid gland—Graves' disease	0.000717	0.00543	CbGeAlD
Carvedilol—PTGS1—thyroid gland—Graves' disease	0.000691	0.00523	CbGeAlD
Carvedilol—ABCB1—pituitary gland—Graves' disease	0.000474	0.00359	CbGeAlD
Carvedilol—ABCB1—adipose tissue—Graves' disease	0.000472	0.00358	CbGeAlD
Carvedilol—SELE—Hemostasis—IL2RA—Graves' disease	0.00045	0.0039	CbGpPWpGaD
Carvedilol—NDUFC2—Metabolism—GC—Graves' disease	0.000445	0.00386	CbGpPWpGaD
Carvedilol—VCAM1—Extracellular matrix organization—ICAM1—Graves' disease	0.000433	0.00375	CbGpPWpGaD
Carvedilol—VCAM1—Cytokine Signaling in Immune system—HLA-DRB1—Graves' disease	0.00043	0.00373	CbGpPWpGaD
Carvedilol—VEGFA—SHP2 signaling—IFNG—Graves' disease	0.000423	0.00367	CbGpPWpGaD
Carvedilol—ADRB1—G alpha (s) signalling events—TSHR—Graves' disease	0.000421	0.00364	CbGpPWpGaD
Carvedilol—GJA1—Myometrial Relaxation and Contraction Pathways—IL1B—Graves' disease	0.000413	0.00358	CbGpPWpGaD
Carvedilol—VCAM1—Cytokine Signaling in Immune system—ICAM1—Graves' disease	0.000413	0.00358	CbGpPWpGaD
Carvedilol—ADRB2—G alpha (s) signalling events—TSHR—Graves' disease	0.000411	0.00356	CbGpPWpGaD
Carvedilol—GJA1—SIDS Susceptibility Pathways—IL1B—Graves' disease	0.000411	0.00356	CbGpPWpGaD
Carvedilol—ABCB1—thyroid gland—Graves' disease	0.000408	0.00309	CbGeAlD
Carvedilol—HIF1A—SIDS Susceptibility Pathways—IL1B—Graves' disease	0.000396	0.00343	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—HLA-E—Graves' disease	0.000384	0.00333	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—CD40—Graves' disease	0.000375	0.00325	CbGpPWpGaD
Carvedilol—GJA1—Spinal Cord Injury—TNF—Graves' disease	0.000373	0.00323	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—CTLA4—Graves' disease	0.00037	0.0032	CbGpPWpGaD
Carvedilol—PTGS1—Overview of nanoparticle effects—TNF—Graves' disease	0.000367	0.00318	CbGpPWpGaD
Carvedilol—XDH—Selenium Micronutrient Network—IFNG—Graves' disease	0.000356	0.00308	CbGpPWpGaD
Carvedilol—ADRB3—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000338	0.00293	CbGpPWpGaD
Carvedilol—NDUFC2—Metabolism—B3GNT2—Graves' disease	0.000338	0.00293	CbGpPWpGaD
Carvedilol—HIF1A—Adipogenesis—TNF—Graves' disease	0.000333	0.00288	CbGpPWpGaD
Carvedilol—VEGFA—Allograft Rejection—IFNG—Graves' disease	0.00033	0.00286	CbGpPWpGaD
Carvedilol—VEGFA—Aryl Hydrocarbon Receptor—TNF—Graves' disease	0.00033	0.00286	CbGpPWpGaD
Carvedilol—XDH—Selenium Micronutrient Network—IL1B—Graves' disease	0.000317	0.00275	CbGpPWpGaD
Carvedilol—VCAM1—Cytokine Signaling in Immune system—IFNG—Graves' disease	0.000314	0.00272	CbGpPWpGaD
Carvedilol—HIF1A—Disease—B3GNT2—Graves' disease	0.000311	0.00269	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—HLA-DQB1—Graves' disease	0.000304	0.00264	CbGpPWpGaD
Carvedilol—GJA1—SIDS Susceptibility Pathways—TNF—Graves' disease	0.000298	0.00258	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—IFIH1—Graves' disease	0.000296	0.00256	CbGpPWpGaD
Carvedilol—VEGFA—Allograft Rejection—IL1B—Graves' disease	0.000295	0.00255	CbGpPWpGaD
Carvedilol—HIF1A—SIDS Susceptibility Pathways—TNF—Graves' disease	0.000288	0.00249	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—CD8A—Graves' disease	0.000284	0.00246	CbGpPWpGaD
Carvedilol—VCAM1—Cytokine Signaling in Immune system—IL1B—Graves' disease	0.00028	0.00243	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—HLA-B—Graves' disease	0.000273	0.00237	CbGpPWpGaD
Carvedilol—VEGFA—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	0.000258	0.00223	CbGpPWpGaD
Carvedilol—ADRB3—GPCR ligand binding—TSHR—Graves' disease	0.000257	0.00223	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—HLA-A—Graves' disease	0.000253	0.0022	CbGpPWpGaD
Carvedilol—VEGFA—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	0.000249	0.00215	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—HLA-E—Graves' disease	0.000233	0.00202	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—HLA-E—Graves' disease	0.000232	0.00201	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—HLA-DRB1—Graves' disease	0.000232	0.00201	CbGpPWpGaD
Carvedilol—XDH—Selenium Micronutrient Network—TNF—Graves' disease	0.00023	0.00199	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—CD40—Graves' disease	0.000228	0.00197	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—CD40—Graves' disease	0.000227	0.00196	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—CTLA4—Graves' disease	0.000224	0.00194	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—CTLA4—Graves' disease	0.000223	0.00194	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—ICAM1—Graves' disease	0.000222	0.00193	CbGpPWpGaD
Carvedilol—ADRA1D—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.00022	0.00191	CbGpPWpGaD
Carvedilol—VEGFA—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	0.00022	0.00191	CbGpPWpGaD
Carvedilol—PTGS1—Selenium Micronutrient Network—ICAM1—Graves' disease	0.000219	0.0019	CbGpPWpGaD
Carvedilol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000218	0.00189	CbGpPWpGaD
Carvedilol—VEGFA—Allograft Rejection—TNF—Graves' disease	0.000214	0.00185	CbGpPWpGaD
Carvedilol—ADRB1—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.0002	0.00174	CbGpPWpGaD
Carvedilol—ADRA2B—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000199	0.00172	CbGpPWpGaD
Carvedilol—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—Graves' disease	0.000197	0.00171	CbGpPWpGaD
Carvedilol—ADRB2—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000196	0.0017	CbGpPWpGaD
Carvedilol—ADRA2C—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000186	0.00161	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—HLA-DQB1—Graves' disease	0.000185	0.0016	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—HLA-DQB1—Graves' disease	0.000184	0.00159	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000183	0.00158	CbGpPWpGaD
Carvedilol—ADRA1B—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000183	0.00158	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—TSHR—Graves' disease	0.00018	0.00156	CbGpPWpGaD
Carvedilol—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	0.000176	0.00152	CbGpPWpGaD
Carvedilol—XDH—Metabolism—GC—Graves' disease	0.000174	0.00151	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—CD8A—Graves' disease	0.000172	0.00149	CbGpPWpGaD
Carvedilol—VEGFA—SIDS Susceptibility Pathways—IL1B—Graves' disease	0.000171	0.00148	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR ligand binding—TSHR—Graves' disease	0.000168	0.00145	CbGpPWpGaD
Carvedilol—PTGS1—Selenium Micronutrient Network—IFNG—Graves' disease	0.000167	0.00144	CbGpPWpGaD
Carvedilol—ADRB3—GPCR ligand binding—CXCL10—Graves' disease	0.000166	0.00144	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—HLA-B—Graves' disease	0.000166	0.00144	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—HLA-B—Graves' disease	0.000165	0.00143	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—CD4—Graves' disease	0.000163	0.00141	CbGpPWpGaD
Carvedilol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000162	0.00141	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—FASLG—Graves' disease	0.000162	0.0014	CbGpPWpGaD
Carvedilol—ADRA2B—G alpha (i) signalling events—CXCL10—Graves' disease	0.000161	0.0014	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—FAS—Graves' disease	0.000156	0.00135	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—IL2RA—Graves' disease	0.000155	0.00135	CbGpPWpGaD
Carvedilol—KCNH2—SIDS Susceptibility Pathways—IL1B—Graves' disease	0.000155	0.00134	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—IL2RA—Graves' disease	0.000155	0.00134	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—HLA-A—Graves' disease	0.000154	0.00133	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—HLA-A—Graves' disease	0.000153	0.00133	CbGpPWpGaD
Carvedilol—ADRB1—GPCR ligand binding—TSHR—Graves' disease	0.000153	0.00132	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR ligand binding—TSHR—Graves' disease	0.000151	0.00131	CbGpPWpGaD
Carvedilol—ADRA2C—G alpha (i) signalling events—CXCL10—Graves' disease	0.000151	0.00131	CbGpPWpGaD
Carvedilol—ADRA2A—Class A/1 (Rhodopsin-like receptors)—TSHR—Graves' disease	0.000151	0.00131	CbGpPWpGaD
Carvedilol—ADRB2—GPCR ligand binding—TSHR—Graves' disease	0.000149	0.00129	CbGpPWpGaD
Carvedilol—PTGS1—Selenium Micronutrient Network—IL1B—Graves' disease	0.000149	0.00129	CbGpPWpGaD
Carvedilol—ADRB3—GPCR downstream signaling—TSHR—Graves' disease	0.000145	0.00126	CbGpPWpGaD
Carvedilol—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000142	0.00123	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR ligand binding—TSHR—Graves' disease	0.000141	0.00122	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—HLA-DRB1—Graves' disease	0.00014	0.00122	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—HLA-DRB1—Graves' disease	0.00014	0.00121	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR ligand binding—TSHR—Graves' disease	0.000139	0.00121	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—ICAM1—Graves' disease	0.000135	0.00117	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—TSHR—Graves' disease	0.000132	0.00114	CbGpPWpGaD
Carvedilol—XDH—Metabolism—B3GNT2—Graves' disease	0.000132	0.00114	CbGpPWpGaD
Carvedilol—ADRA2B—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	0.00013	0.00112	CbGpPWpGaD
Carvedilol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.00013	0.00112	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000129	0.00112	CbGpPWpGaD
Carvedilol—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000128	0.00111	CbGpPWpGaD
Carvedilol—CYP1A1—Aryl Hydrocarbon Receptor—TNF—Graves' disease	0.000128	0.00111	CbGpPWpGaD
Carvedilol—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—Graves' disease	0.000128	0.00111	CbGpPWpGaD
Carvedilol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000127	0.0011	CbGpPWpGaD
Carvedilol—HIF1A—Disease—HLA-A—Graves' disease	0.000126	0.00109	CbGpPWpGaD
Carvedilol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—Graves' disease	0.000126	0.00109	CbGpPWpGaD
Carvedilol—VEGFA—SIDS Susceptibility Pathways—TNF—Graves' disease	0.000124	0.00108	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR ligand binding—TSHR—Graves' disease	0.000124	0.00107	CbGpPWpGaD
Carvedilol—ADRA2A—G alpha (i) signalling events—CXCL10—Graves' disease	0.000122	0.00106	CbGpPWpGaD
Carvedilol—ADRA2C—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	0.000121	0.00105	CbGpPWpGaD
Carvedilol—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.00012	0.00104	CbGpPWpGaD
Carvedilol—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000118	0.00102	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—CXCL10—Graves' disease	0.000117	0.00101	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR ligand binding—TSHR—Graves' disease	0.000115	0.000995	CbGpPWpGaD
Carvedilol—VEGFA—Hemostasis—IL2RA—Graves' disease	0.000113	0.000982	CbGpPWpGaD
Carvedilol—KCNH2—SIDS Susceptibility Pathways—TNF—Graves' disease	0.000113	0.000975	CbGpPWpGaD
Carvedilol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	0.000112	0.000972	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR ligand binding—CXCL10—Graves' disease	0.000108	0.000938	CbGpPWpGaD
Carvedilol—PTGS1—Selenium Micronutrient Network—TNF—Graves' disease	0.000108	0.000934	CbGpPWpGaD
Carvedilol—VEGFA—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	0.000106	0.000914	CbGpPWpGaD
Carvedilol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	0.000105	0.000908	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—IFNG—Graves' disease	0.000103	0.000889	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—IFNG—Graves' disease	0.000102	0.000885	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—CD4—Graves' disease	9.9e-05	0.000858	CbGpPWpGaD
Carvedilol—ADRB1—GPCR ligand binding—CXCL10—Graves' disease	9.87e-05	0.000855	CbGpPWpGaD
Carvedilol—ADRA2A—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	9.83e-05	0.000852	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR ligand binding—CXCL10—Graves' disease	9.78e-05	0.000847	CbGpPWpGaD
Carvedilol—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL10—Graves' disease	9.74e-05	0.000844	CbGpPWpGaD
Carvedilol—ADRB2—GPCR ligand binding—CXCL10—Graves' disease	9.65e-05	0.000836	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism of lipids and lipoproteins—GC—Graves' disease	9.61e-05	0.000833	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—TSHR—Graves' disease	9.47e-05	0.00082	CbGpPWpGaD
Carvedilol—ADRB3—GPCR downstream signaling—CXCL10—Graves' disease	9.39e-05	0.000814	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—IL1B—Graves' disease	9.15e-05	0.000793	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR ligand binding—CXCL10—Graves' disease	9.13e-05	0.000791	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—IL1B—Graves' disease	9.11e-05	0.00079	CbGpPWpGaD
Carvedilol—ABCB1—Transmembrane transport of small molecules—GABRA3—Graves' disease	9.1e-05	0.000788	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR ligand binding—CXCL10—Graves' disease	8.99e-05	0.000779	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—IL2RA—Graves' disease	8.91e-05	0.000772	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—TSHR—Graves' disease	8.63e-05	0.000748	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—TSHR—Graves' disease	8.6e-05	0.000745	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—TSHR—Graves' disease	8.55e-05	0.000741	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—CXCL10—Graves' disease	8.53e-05	0.000739	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—TSHR—Graves' disease	8.44e-05	0.000731	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism of lipids and lipoproteins—GC—Graves' disease	8.21e-05	0.000712	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—GC—Graves' disease	8.16e-05	0.000707	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—GC—Graves' disease	8.14e-05	0.000706	CbGpPWpGaD
Carvedilol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—Graves' disease	8.14e-05	0.000705	CbGpPWpGaD
Carvedilol—CYP1A2—Aryl Hydrocarbon Receptor—TNF—Graves' disease	8.14e-05	0.000705	CbGpPWpGaD
Carvedilol—HIF1A—Disease—CD4—Graves' disease	8.1e-05	0.000702	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—TSHR—Graves' disease	7.99e-05	0.000692	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR ligand binding—CXCL10—Graves' disease	7.98e-05	0.000692	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	7.97e-05	0.000691	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—TSHR—Graves' disease	7.86e-05	0.000681	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—TSHR—Graves' disease	7.84e-05	0.000679	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TSHR—Graves' disease	7.8e-05	0.000676	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TSHR—Graves' disease	7.78e-05	0.000674	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—TSHR—Graves' disease	7.76e-05	0.000673	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	7.69e-05	0.000666	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—TSHR—Graves' disease	7.66e-05	0.000664	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR ligand binding—CXCL10—Graves' disease	7.42e-05	0.000643	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—TSHR—Graves' disease	7.25e-05	0.000628	CbGpPWpGaD
Carvedilol—ADRB3—GPCR downstream signaling—IL2RA—Graves' disease	7.18e-05	0.000622	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—TSHR—Graves' disease	7.14e-05	0.000618	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—TSHR—Graves' disease	6.98e-05	0.000605	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—IL2RA—Graves' disease	6.68e-05	0.000579	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—GC—Graves' disease	6.63e-05	0.000574	CbGpPWpGaD
Carvedilol—ABCB1—Allograft Rejection—TNF—Graves' disease	6.61e-05	0.000573	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—IL2RA—Graves' disease	6.52e-05	0.000565	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—TSHR—Graves' disease	6.49e-05	0.000562	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—TSHR—Graves' disease	6.34e-05	0.000549	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—IL2RA—Graves' disease	6.24e-05	0.000541	CbGpPWpGaD
Carvedilol—ADRA2C—Metabolism—B3GNT2—Graves' disease	6.18e-05	0.000536	CbGpPWpGaD
Carvedilol—PTGS1—Metabolism—B3GNT2—Graves' disease	6.17e-05	0.000535	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—CXCL10—Graves' disease	6.12e-05	0.00053	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—GC—Graves' disease	6.09e-05	0.000527	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—TSHR—Graves' disease	5.89e-05	0.00051	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—GC—Graves' disease	5.74e-05	0.000497	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—CXCL10—Graves' disease	5.58e-05	0.000483	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—CXCL10—Graves' disease	5.56e-05	0.000481	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—CXCL10—Graves' disease	5.52e-05	0.000479	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—CXCL10—Graves' disease	5.45e-05	0.000473	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—CXCL10—Graves' disease	5.16e-05	0.000447	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TSHR—Graves' disease	5.08e-05	0.00044	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—CXCL10—Graves' disease	5.08e-05	0.00044	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—IL2RA—Graves' disease	5.07e-05	0.000439	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—CXCL10—Graves' disease	5.06e-05	0.000439	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—CXCL10—Graves' disease	5.04e-05	0.000437	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—CXCL10—Graves' disease	5.03e-05	0.000436	CbGpPWpGaD
Carvedilol—ADRA2A—Metabolism—B3GNT2—Graves' disease	5.02e-05	0.000435	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—CXCL10—Graves' disease	5.02e-05	0.000435	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—CXCL10—Graves' disease	4.95e-05	0.000429	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—TNF—Graves' disease	4.93e-05	0.000428	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—CXCL10—Graves' disease	4.69e-05	0.000406	CbGpPWpGaD
Carvedilol—ADRA1D—GPCR downstream signaling—IL2RA—Graves' disease	4.68e-05	0.000405	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TSHR—Graves' disease	4.63e-05	0.000401	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—CXCL10—Graves' disease	4.61e-05	0.0004	CbGpPWpGaD
Carvedilol—CYP2E1—Metabolism—B3GNT2—Graves' disease	4.61e-05	0.0004	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TSHR—Graves' disease	4.59e-05	0.000397	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—GC—Graves' disease	4.58e-05	0.000397	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TSHR—Graves' disease	4.53e-05	0.000392	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—CXCL10—Graves' disease	4.51e-05	0.000391	CbGpPWpGaD
Carvedilol—CYP1A1—Metabolism—B3GNT2—Graves' disease	4.35e-05	0.000377	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—GC—Graves' disease	4.32e-05	0.000374	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TSHR—Graves' disease	4.28e-05	0.000371	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—GC—Graves' disease	4.28e-05	0.000371	CbGpPWpGaD
Carvedilol—ADRB1—GPCR downstream signaling—IL2RA—Graves' disease	4.26e-05	0.000369	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—IL2RA—Graves' disease	4.25e-05	0.000368	CbGpPWpGaD
Carvedilol—ADRA2B—GPCR downstream signaling—IL2RA—Graves' disease	4.22e-05	0.000366	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TSHR—Graves' disease	4.22e-05	0.000365	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—CXCL10—Graves' disease	4.19e-05	0.000363	CbGpPWpGaD
Carvedilol—ADRB2—GPCR downstream signaling—IL2RA—Graves' disease	4.17e-05	0.000361	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—CXCL10—Graves' disease	4.1e-05	0.000355	CbGpPWpGaD
Carvedilol—ADRA2C—GPCR downstream signaling—IL2RA—Graves' disease	3.94e-05	0.000342	CbGpPWpGaD
Carvedilol—ADRA1B—GPCR downstream signaling—IL2RA—Graves' disease	3.88e-05	0.000336	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—IL2RA—Graves' disease	3.87e-05	0.000335	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—IL2RA—Graves' disease	3.85e-05	0.000334	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—IL2RA—Graves' disease	3.84e-05	0.000333	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—IL2RA—Graves' disease	3.83e-05	0.000332	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—CXCL10—Graves' disease	3.81e-05	0.00033	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—IL2RA—Graves' disease	3.79e-05	0.000328	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TSHR—Graves' disease	3.74e-05	0.000324	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—GC—Graves' disease	3.66e-05	0.000317	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—IL2RA—Graves' disease	3.58e-05	0.00031	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—IL2RA—Graves' disease	3.52e-05	0.000305	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TSHR—Graves' disease	3.48e-05	0.000301	CbGpPWpGaD
Carvedilol—ABCB1—Metabolism—B3GNT2—Graves' disease	3.47e-05	0.000301	CbGpPWpGaD
Carvedilol—ADRA1A—GPCR downstream signaling—IL2RA—Graves' disease	3.45e-05	0.000299	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—CXCL10—Graves' disease	3.28e-05	0.000284	CbGpPWpGaD
Carvedilol—CYP2D6—Metabolism—B3GNT2—Graves' disease	3.27e-05	0.000284	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	3.26e-05	0.000283	CbGpPWpGaD
Carvedilol—CYP2C9—Metabolism—B3GNT2—Graves' disease	3.24e-05	0.000281	CbGpPWpGaD
Carvedilol—ADRA2A—GPCR downstream signaling—IL2RA—Graves' disease	3.2e-05	0.000278	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—IL2RA—Graves' disease	3.13e-05	0.000271	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—CXCL10—Graves' disease	2.99e-05	0.000259	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—CXCL10—Graves' disease	2.96e-05	0.000257	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—CXCL10—Graves' disease	2.93e-05	0.000254	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—IL2RA—Graves' disease	2.91e-05	0.000252	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—GC—Graves' disease	2.82e-05	0.000245	CbGpPWpGaD
Carvedilol—CYP1A2—Metabolism—B3GNT2—Graves' disease	2.77e-05	0.00024	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—CXCL10—Graves' disease	2.77e-05	0.00024	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—CXCL10—Graves' disease	2.72e-05	0.000236	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—IL2RA—Graves' disease	2.51e-05	0.000217	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—CXCL10—Graves' disease	2.42e-05	0.00021	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—IL2RA—Graves' disease	2.29e-05	0.000198	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—IL2RA—Graves' disease	2.27e-05	0.000196	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—CXCL10—Graves' disease	2.25e-05	0.000195	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—IL2RA—Graves' disease	2.24e-05	0.000194	CbGpPWpGaD
Carvedilol—CYP3A4—Metabolism—B3GNT2—Graves' disease	2.14e-05	0.000185	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—IL2RA—Graves' disease	2.12e-05	0.000183	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—IL2RA—Graves' disease	2.08e-05	0.00018	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—IL2RA—Graves' disease	1.85e-05	0.00016	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—IL2RA—Graves' disease	1.72e-05	0.000149	CbGpPWpGaD
